Takeda Pharmaceutical Company Limited is poised to announce its financial results for the third quarter of fiscal year 2026 on January 29, 2026. The earnings report, expected before the market opens, has analysts projecting earnings of $0.55 per share and revenue of $7.8144 billion for the quarter.
In its fiscal year 2025 guidance, Takeda has indicated an earnings per share (EPS) target ranging from $3.250 to $3.250. Investors can find additional details on the upcoming earnings call scheduled for 5:30 AM ET through the company’s Q3 2026 earnings overview page.
The last earnings report, released on October 30, 2025, revealed an EPS of $0.44, aligning with analyst expectations. During that quarter, Takeda reported a net margin of 0.86% and a return on equity of 10.32%, with revenues reaching $7.30 billion, falling short of the anticipated $8.01 billion.
Market analysts maintain a generally cautious outlook for Takeda. Currently, the consensus among analysts is that the company will record an EPS of $2 for both the current and next fiscal years.
As of Thursday, Takeda’s stock opened at $16.11, reflecting a 0.3% decrease. Over the past year, the stock has fluctuated between a low of $12.80 and a high of $16.48. The company’s market capitalization stands at $51.25 billion, with a price-to-earnings ratio of 201.31 and a beta of 0.03. Its current and quick ratios are 1.37 and 0.76, respectively, while the debt-to-equity ratio is 0.61.
Analyst Ratings and Market Sentiment
Recent coverage from Wall Street analysts provides further insight into Takeda’s market position. On January 13, 2026, Morgan Stanley initiated coverage with an “overweight” rating. Conversely, Weiss Ratings reaffirmed a “hold (C-)” rating on December 29, 2025. The mix of ratings includes one Buy, one Hold, and one Sell, leading to a consensus rating of “Hold” according to MarketBeat.com.
Takeda Pharmaceutical, headquartered in Tokyo, is a prominent multinational biopharmaceutical company with a history that dates back to 1781. The organization focuses on researching, developing, and commercializing pharmaceutical products across multiple therapeutic areas. As a fully integrated R&D-driven healthcare company, Takeda is committed to delivering specialty medicines and therapies to patients worldwide.
Investors and analysts alike are closely monitoring the upcoming earnings announcement, as it will provide crucial insights into Takeda’s financial health and future performance.
